PR

Austrianova publishes use of Cell-in-a-Box® encapsulation technology for treatment of diabetes

Singapore 22nd September, 2014

Austrianova, and its partner Nuvilex Inc., announced today the publication of a scientific article in the international, online, journal *Diabetes Research and Treatment: Open Access*. The article reviews the current status of the use of cell encapsulation for the treatment of diabetes and highlights the application of the Cell-in-a-Box® encapsulation technology. Besides discussing some of the characteristics of this technology that make it ideal for the treatment of diabetes, it summarises some of the encouraging data that has already been obtained by Austrianova and it's partners in animal models of diabetes.

The article can be accessed online at: http://austrianova.com/wp-content/uploads/2014/09/DRTOA-1-102-final.compressed.pdf

Prof. Walter H Gunzburg, Chairman of the Board of Austrianova, said "Austrianova is a pioneer in the development of the Cell-in-a-Box® encapsulation technology for the treatment of a variety of diseases including diabetes. This publication explains why the Cell-in-a-Box® technology is ideally suited for this purpose and also describes preclinical data. Austrianova is working closely with Nuvilex, Inc. and others so that this treatment will be advanced to the market as rapidly as possible".

Dr. Brian Salmons, CEO of Austrianova, stated "We are happy that our paper has appeared in *Diabetes Research and Treatment* since this journal focuses on all aspects of diabetes including innovative research, preventive measures, therapeutic treatment, diabetic education, management, and related disorders" and is available online in open access form.

About Austrianova:
Austrianova, part of the SG Austria Group, is a biotech company with a global footprint and headquarters in Singapore. Austrianova utilizes a novel and proprietary technology for the encapsulation of living mammalian (Cell-in-a-Box®) and bacterial (Bac-in-a-Box®) cells. Cell-in-a-Box® protects the encapsulated cells from rejection by the immune system, allows cells to be easily transported, stored and implanted at specific sites in patients. The technology, which has been proven safe and efficacious in clinical trials carried out in Europe, allows companies to develop any kind of cells as a one-for-all living pharmaceutical. Bac-in-a-Box® is a similar protective device adapted for encapsulation of probiotic bacteria where it has human food and animal feed applications due to its ability for extending storage under lyophilized conditions and protection in stomach acid.